Medical Information Only. Always consult your healthcare provider before enrolling in any clinical trial.
NCT04783428 · ClinicalTrials.gov registry record
Tumor-induced Osteomalacia Disease Monitoring Program
A clinical trial of Tumor-induced Osteomalacia (TIO), sponsored by Ultragenyx Pharmaceutical.
- Active
- Registry status
- 23
- Enrollment target
- 6
- Study locations
NCT04783428: Active study of Tumor-induced Osteomalacia (TIO), sponsored by Ultragenyx Pharmaceutical.
NCT04783428 is a study of Tumor-induced Osteomalacia (TIO) that is active but no longer recruiting, run by Ultragenyx Pharmaceutical. The registered enrollment target is 23 participants. The trial reports 6 study locations across 6 states. According to ClinicalTrials.gov, the official US trial registry.
The verdict
NCT04783428, a study of Tumor-induced Osteomalacia (TIO), is active but no longer recruiting, sponsored by Ultragenyx Pharmaceutical.
- ACTIVE NOT RECRUITING
- Registry status
- 23 participants
- Enrollment target
- 6
- Study locations
Study Summary
The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime in patients with TIO irrespective of their treatment status.
Conditions Studied
Interventions
- OTHER No intervention
Study Locations (6)
Connecticut
- Yale University - New Haven
Indiana
- Indiana University - Bloomington
Maryland
- Johns Hopkins University - Baltimore
Tennessee
- Vanderbilt University Medical Center - Nashville
Virginia
- University of Virginia - Charlottesville
Other
- IDIM - Instituto de Diagnóstico e Investigaciones Metabólicas - Buenos Aires
Trial Details
| Field | Value |
|---|---|
| Enrollment Target | 23 participants |
| Start Date | 2022-01-31 |
| Est. Completion | 2032-02-28 |
What the registry record for NCT04783428 still lists
NCT04783428 is an observational study that tracks outcomes without assigning an intervention. The registry caps enrollment at 23 participants, a relatively small participant target.
The record links to 1 condition, with Tumor-induced Osteomalacia (TIO) appearing as the primary indexed condition, and to 1 intervention - of which No intervention is the first listed.
NCT04783428 lists 6 locations in 6 states (Connecticut, Indiana, Maryland).
Frequently Asked Questions
What is clinical trial NCT04783428 about?
NCT04783428 is a clinical study titled "Tumor-induced Osteomalacia Disease Monitoring Program". The objectives of this observational study are to assess the long-term safety and long-term effectiveness of burosumab in patients with TIO who are being treated with burosumab as prescribed by their physician and to monitor the course of the underlying phosphaturic mesenchymal tumor (PMT) overtime ...
What is the current status of trial NCT04783428?
This trial is currently active not recruiting. The enrollment target is 23 participants. The study started on 2022-01-31. Estimated completion is 2032-02-28.
What conditions does trial NCT04783428 study?
This clinical trial studies the following conditions: Tumor-induced Osteomalacia (TIO).
What interventions are being tested in trial NCT04783428?
The interventions under investigation include: No intervention (OTHER).
Who is sponsoring clinical trial NCT04783428?
This trial is sponsored by Ultragenyx Pharmaceutical, which has 52 total clinical trials registered on ClinicalTrials.gov.
Where is trial NCT04783428 being conducted?
This trial has 6 study locations across Connecticut, Indiana, Maryland, Tennessee, Virginia. Contact the study sites directly through ClinicalTrials.gov for enrollment availability.
Learn More About Clinical Trials
Similar trials for Tumor-induced Osteomalacia (TIO)
Matched on the same primary condition, ranked to surface studies in the same phase first, then by recruiting status, no relevance scoring or editorial curation.
Nationwide trials with similar profiles
Cross-condition peers matched on enrollment target and registry start date, not the same-condition list above.
Similar enrollment target
- NCT03616041 · 23 participants
Capsule Endoscopy for Severe Hematochezia
- NCT04348747 · 23 participants · Phase 2
Dendritic Cell Vaccines Against Her2/Her3 and Pembrolizumab for the Treatment of Brain Metastasis From Triple Negative Breast Cancer or HER2+ Breast Cancer
- NCT04587687 · 23 participants · Phase 2
Brentuximab Vedotin and Bendamustine for the Treatment of Relapsed or Refractory Follicular Lymphoma
- NCT04715022 · 23 participants · Phase 1
Sympathetic-vascular Dysfunction in Obesity and Insulin Resistance (Vitamin C Study)
Similar registry start date
- NCT05962346 · started 2026-12 · NA
Fetal Endoscopic Tracheal Occlusion for Congenital Diaphragmatic Hernia
- NCT07125183 · started 2026-12 · Phase 2
Study on Efficacy and Tolerability of Weekly Doxorubicin in Elderly Patients With Advanced or Metastatic Leiomyosarcoma
- NCT07292298 · started 2026-11 · Phase 2
Phase 2 Single-Arm Rectal Cancer Brachytherapy for Patients With Low-Lying Residual Adenocarcinoma After Total Neoadjuvant Therapy to Improve Organ Preservation Rates
- NCT04263285 · started 2026-10 · NA
Treatment of Depression Post-SCI